Kerri Wilks

1.8k total citations · 1 hit paper
9 papers, 709 citations indexed

About

Kerri Wilks is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Kerri Wilks has authored 9 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Psychiatry and Mental health, 3 papers in Pathology and Forensic Medicine and 3 papers in Physiology. Recurrent topics in Kerri Wilks's work include Migraine and Headache Studies (7 papers), Sympathectomy and Hyperhidrosis Treatments (2 papers) and Trigeminal Neuralgia and Treatments (2 papers). Kerri Wilks is often cited by papers focused on Migraine and Headache Studies (7 papers), Sympathectomy and Hyperhidrosis Treatments (2 papers) and Trigeminal Neuralgia and Treatments (2 papers). Kerri Wilks collaborates with scholars based in United States, Denmark and United Kingdom. Kerri Wilks's co-authors include Richard B. Lipton, K. Einhäupl, Hartmut Göbel, Alexander Mauskop, Jeff Smith, Messoud Ashina, David Kudrow, Robert R. Bargar, David W. Dodick and Joe Hirman and has published in prestigious journals such as Neurology, The Lancet Neurology and Pain.

In The Last Decade

Kerri Wilks

9 papers receiving 666 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

2014 299 citations David W. Dodick, Peter J. Goadsby et al. The Lancet Neurology profile →

Peers

Countries citing papers authored by Kerri Wilks

Since Specialization

Citations

This map shows the geographic impact of Kerri Wilks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerri Wilks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerri Wilks more than expected).

Fields of papers citing papers by Kerri Wilks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerri Wilks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerri Wilks. The network helps show where Kerri Wilks may publish in the future.

Co-authorship network of co-authors of Kerri Wilks

This figure shows the co-authorship network connecting the top 25 collaborators of Kerri Wilks. A scholar is included among the top collaborators of Kerri Wilks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerri Wilks. Kerri Wilks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Eptinezumab for the Prevention of Episodic Migraine Through 1 Year: Results from the Phase 3 PROMISE-1 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy–1) Trial (S38.003) 2019 ·Neurology ·Joel R. Saper, Kerri Wilks, (unknown), Roger Cady, Barbara Schaeffler, David M. Biondi, Joe Hirman, Jeff Smith	1
2	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial breakdown → 2014 ·The Lancet Neurology ·David W. Dodick, Peter J. Goadsby, Stephen D. Silberstein, Richard B. Lipton, Jes Olesen, Messoud Ashina, Kerri Wilks, David Kudrow, Robin Kroll, (unknown), Robert R. Bargar, Joe Hirman, Jeff Smith	299
3	Long term safety of the sumatriptan iontophoretic transdermal patch, NP101, for acute migraine: a 12 month, repeat use, open label study 2012 ·Timothy R. Smith, Mark Pierce, Kerri Wilks, Carol O’Neill, (unknown)	2
4	P3‐425: Safety, tolerability and efficacy of lecozotan SR in patients with mild‐to‐moderate Alzheimer's disease used as monotherapy or adjunctively with a cholinesterase inhibitor 2012 ·Alzheimer s & Dementia ·Kevin Booth, Yonggang Zhao, Yue Hua, Kerri Wilks, Paul R. Solomon, (unknown), (unknown), Sangeeta Raje, Ronald S. Black	1
5	Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies 2006 ·Pain ·Aaron I. Vinik, Michael Tuchman, Beth Safirstein, Clinton N. Corder, Louis Kirby, Kerri Wilks, Steve Quessy, David Blum, J. Grainger, J. D. White, Marianne T. Silver	123
6	Acetaminophen in the treatment of headaches associated with dipyridamole-aspirin combination 2004 ·Neurology ·Richard B. Lipton, Marcelo E. Bigal, K. Kolodner, Philip B. Gorelick, Kerri Wilks, (unknown), Giora Davidai	17
7	Petasites hybridusroot (butterbur) is an effective preventive treatment for migraine 2004 ·Neurology ·Richard B. Lipton, Hartmut Göbel, K. Einhäupl, Kerri Wilks, Alexander Mauskop	167
8	Diagnostic lessons from the spectrum study. 2003 ·Headache The Journal of Head and Face Pain ·RB Lipton, (unknown), WF Stewart, Kerri Wilks, Chris Hall	3
9	Diagnostic lessons from the Spectrum Study 2002 ·Neurology ·RB Lipton, Roger Cady, Walter F. Stewart, Kerri Wilks, Charles B. Hall	96

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact